Wednesday 29 October 2008

Sun Pharmaceutical an outperformer: Karvy

Karvy Stock Broking has maintained its outperformer rating on Sun Pharmaceutical Industries with a target of Rs 1387 in its October 29, 2008 research report. "The company's net revenues for the quarter were up by 76 % to Rs 11778 million. Profits for the quarter have moved up by 135 % to Rs 5127 million with the help of higher other income."

"We have marginally decreased our FY 2009 estimates by 3.4 % to Rs 87.9 mainly on account of lower gross margins, higher staff and other expenses despite higher revenue traction. We have marginally increased our FY 2010 estimates by 3.1 % to Rs 99.1 mainly on back of higher other income. We however downgrade our price target on account of compression in valuations. We value the core business of the company at 18x FY 2009E and value it at 1272 while we value the FTF opportunity of Rs 28.4 at 4x and value it at Rs 114. We arrive at a value of Rs 1,387 for the company. We however continue to rate the stock as Outperformer," says Karvy Stock Broking's research report.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Source: Moneycontrol

Posted by Harsh at 08:17

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)
DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.